Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.

European journal of cancer (Oxford, England : 1990) - 1 May 2021

Mao Lili, Dai Jie, Cao Yabin, Bai Xue, Sheng Xinan, Chi Zhihong, Cui Chuanliang, Kong Yan, Zhang Yanxiang, Wu Lin, Wang Xuan, Tang Bixia, Lian Bin, Yan Xieqiao, Li Siming, Zhou Li, Wei Xiaoting, Li Caili, Qi Zhonghui, Si Lu, Guo Jun

Abstract excerpt

BACKGROUND: Genetic aberrations in the cyclin-dependent kinase (CDK)4 pathway occur in 82% of patients with acral melanoma (AM), which is the predominant subtype of melanoma in China. We aimed to evaluate the anti-tumour activity of palbociclib, a selective CDK4/6 inhibitor, in patients with advanced AM with CDK4 pathway gene aberrations. METHODS: In this phase II trial, patients with advanced AM with CDK4 or/and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Melanoma

Share to Piperazines

Share to Pyridines

Share to Skin Neoplasms

Share to Survival Rate

Source

Identifiers

PMID: 33770575
DOI: 10.1016/j.ejca.2021.02.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.PMID 33770575Read ↗

Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.Semantic proximity Read ↗

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous MelanomaSemantic proximity Read ↗

ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous MelanomaSemantic proximity Read ↗

Frequency of CDK2 , CCNE1 Copy Number Variation in Acral Melanoma and Implications for CDK Inhibitor in Targeted TherapySemantic proximity Read ↗

ERK Hyperactivation Represents a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous MelanomaSemantic proximity Read ↗

ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanomaSemantic proximity Read ↗

Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapySemantic proximity Read ↗

Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment.Semantic proximity Read ↗

Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.Semantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071Semantic proximity Read ↗

Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and TranscriptomicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.